Ikarian Capital »

Monte Rosa Therapeutics shares owned by Ikarian Capital

Quarter-by-quarter ownership of Monte Rosa Therapeutics (GLUE) shares owned by Ikarian Capital from 13F filings

Historical chart of Ikarian Capital investment in Monte Rosa Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Monte Rosa Therapeutics held by Ikarian Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Monte Rosa Therapeutics by Ikarian Capital

Quarter filed Position value Share count Share price at filing
2024-09-30 $1.7M 312k 5.30

More positions owned by Ikarian Capital

Vertex Pharmaceuticals Incorporated Put Option (VRTX)
Amgen Call Option (AMGN)
Spdr Ser Tr S&p Biotech Put Option (XBI)
Tarsus Pharmaceuticals (TARS)
Beigene Sponsored Adr Call Option (BGNE)
Anaptysbio Inc Common Put Option (ANAB)
Crinetics Pharmaceuticals In (CRNX)
Celldex Therapeutics Com New Put Option (CLDX)
Soleno Therapeutics Call Option (SLNO)
Janux Therapeutics Put Option (JANX)
Biohaven Put Option (BHVN)
Miragen Therapeutics Call Option (VRDN)
Immunovant Call Option (IMVT)
Capricor Therapeutics Com New Put Option (CAPR)
Arcus Biosciences Incorporated Call Option (RCUS)

View all positions for Ikarian Capital

Top funds holding Monte Rosa Therapeutics

NEA Management Company
T. Rowe Price Associates
Baker Bros. Advisors
BlackRock
Suvretta Capital Management
Vanguard Group
BlackRock
Aisling Capital Management
Alphabet
Citadel Advisors
Geode Capital Management
Vestal Point Capital
State Street Corporation
Parkwood
ExodusPoint Capital Management

View all funds holding Monte Rosa Therapeutics